Pharmaceutical follow-up for patients on rituximab therapy for non-Hodgkin lymphoma: what is the evidence?

Hegele, Vanessa; Stoll, Paula; Wüst, Diego; Ehrenbrink, Guilherme; Grazziotin, Luiza R; Caregnato, Juliana Prohonoski; Lindenmeyer, Luciane Pereira

doi:10.1007/s11096-013-9780-1

Cited by 3 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In advanced-stage diffuse large B-cell lymphoma, R-CHOP chemotherapy stands as a standard approach, supported by evidence from randomized controlled trials [19]- [21]. Despite advancements, the addition of maintenance rituximab following chemoimmunotherapy has not demonstrated substantial benefits [22], [23].…”

Section: Treatmentmentioning

confidence: 99%

Non-Hodgkin Lymphoma of The Head and Neck: A Literature Review on Its Etiology, Clinical Symptoms, and Treatment

Afifah Naura Andika Putri,

Yusuf,

Hari Susilo

2023

IJRP

View full text Add to dashboard Cite

Non-Hodgkin Lymphoma (NHL) comprises around 90% of all lymphomas, presenting a diverse array of malignant tumors with distinct subtypes. The occurrence of lymphomas in the domain of head and neck malignancies fluctuates from 1% to 17%, contingent on the geographic location and the specific timeframe of the study. Due to the increasing number of NHL cases especially in the head and neck, this research aims to provide a better understanding of its etiology, clinical symptoms, and treatment.

show abstract

Section: Treatmentmentioning

confidence: 99%

Non-Hodgkin Lymphoma of The Head and Neck: A Literature Review on Its Etiology, Clinical Symptoms, and Treatment

Afifah Naura Andika Putri,

Yusuf,

Hari Susilo

2023

IJRP

View full text Add to dashboard Cite

show abstract

“…For over thirty years, CHOP have become the first choice of high-intensity chemotherapy used in aggressive NHL therapy. 6,7 Rituximab was introduced as an anti-CD20 monoclonal antibody in 1997. Rituximab has been proven to be safe and can be used for aggressive NHL therapy combined with standard chemotherapy.…”

Section: Original Articlementioning

confidence: 99%

“…The combination of Rituximab with CHOP is known as R-CHOP. 7,8 CHOP and R-CHOP therapeutic responses in NHL patients in Dr. Soetomo General Hospital Surabaya has not been studied before. This study aims to determine the response of CHOP and R-CHOP therapy in Non-Hodgkin Lymphoma patients in Dr. Soetomo General Hospital Surabaya, as NHL currently becomes one of the most common malignancy in Indonesia.…”

Section: Original Articlementioning

confidence: 99%

CHOP and R-CHOP Therapeutic Responses in Non-Hodgkin Lymphoma Patients in Dr. Soetomo General Hospital Surabaya

Salma

Sedana

Yudho

2018

BHSJ

View full text Add to dashboard Cite

Introduction: Non-Hodgkin Lymphoma (NHL) is a group of lymphoid-derived malignant disease with heterogenic biological and clinical manifestations. For over 30 years, CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) has been the first choice of chemotherapy for aggressive NHL. Later in 1997 Rituximab as anti-CD20 monoclonal antibody was introduced and then combined with CHOP as R-CHOP. The objective of this study is to acknowledge the response of the CHOP and R-CHOP therapy in Non-Hodgkin Lymphoma patients at Dr. Soetomo General Hospital.Methods: The design of this study was retrospective observational study using secondary data obtained from patient’s medical records from 2011 to 2015. The data selected from the medical records are the result of the therapy, as well as patient’s gender and age. Results: The results of patients’ therapy were classified into four categories: The study showed that 51.28% patients had Complete Response, followed by Partial Response (28.21%), Progressive Disease (17.95%), and No Change (2.56%). Sample characteristics showed male patients in higher percentage (66.67%), and the majority of patients’ age between 51-60 years old (30.77%). The use of CHOP and R-CHOP regiment were 76.92% and 20,52% respectively.Conclusion: Most of the patients had a complete response. The CHOP regiment is more commonly used in patients compared to R-CHOP.

show abstract

Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group

et al. 2014

View full text Add to dashboard Cite

Pharmaceutical follow-up for patients on rituximab therapy for non-Hodgkin lymphoma: what is the evidence?

Cited by 3 publications

References 34 publications

Non-Hodgkin Lymphoma of The Head and Neck: A Literature Review on Its Etiology, Clinical Symptoms, and Treatment

Non-Hodgkin Lymphoma of The Head and Neck: A Literature Review on Its Etiology, Clinical Symptoms, and Treatment

CHOP and R-CHOP Therapeutic Responses in Non-Hodgkin Lymphoma Patients in Dr. Soetomo General Hospital Surabaya

Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group

Contact Info

Product

Resources

About